Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : XBIO-015
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : PeriNess
Deal Size : Undisclosed
Deal Type : Collaboration
Xenetic, Partner Enter Clinical Study for DNase in Osteosarcoma, Ewing Sarcoma
Details : The collaboration aims to advance the clinical development of XBIO-015. It is being evaluated for the treatment of relapsed/refractory osteosarcoma and Ewing sarcoma.
Product Name : XBIO-015
Product Type : Enzyme
Upfront Cash : Undisclosed
March 26, 2025
Lead Product(s) : XBIO-015
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : PeriNess
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Deoxyribonuclease I,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xenetic Shows Preclinical Data on DNase I Boosting Immunotherapy Responses
Details : XBIO-020, a DNase I to be delivered to the tumor and secreted by CAR T therapies. It is being evaluated for the treatment of solid tumors.
Product Name : XBIO-020
Product Type : Enzyme
Upfront Cash : Inapplicable
March 13, 2025
Lead Product(s) : Deoxyribonuclease I,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XBIO-015
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : PeriNess
Deal Size : Undisclosed
Deal Type : Agreement
Xenetic Enters Agreement with PeriNess for DNase I Oncology Program Development
Details : Under the agreement, Xenetic aims to advance the development program, XBIO-015 in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma.
Product Name : XBIO-015
Product Type : Enzyme
Upfront Cash : Undisclosed
May 12, 2024
Lead Product(s) : XBIO-015
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : PeriNess
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : VolitionRx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : VolitionRx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SHP656
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from this single-dose study indicate that polysialylation of rFVIII confers a half-life extension similar to that of approved extended half-life products that use PEG or Fc fusion.
Product Name : SHP656
Product Type : Protein
Upfront Cash : Inapplicable
January 14, 2020
Lead Product(s) : SHP656
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable